SCHEMBL4267488

SCHEMBL4267488

NCCn1c(=O)n(S(=O)(=O)c2cccc(Cl)c2)c2cccnc21

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 12/20 0.52
HTR7 P34969 3/20 0.52
HTR2A P28223 2/20 0.52
HTR2C P28335 2/20 0.52
MET P08581 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.47
MMP2 P08253 1/20 0.39
SLC40A1 Q9NP59 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
HSD11B1 P28845 1/20 0.38
NFE2L2 Q16236 2/20 0.38
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4282009 0.88 PKM (0.45) HTR6HTR7HTR2AHTR2CPTGDR2
SCHEMBL4268401 0.87 HTR6 (0.52) HTR6HTR7HTR2AHTR2CMAPT
SCHEMBL4276532 0.87 HTR6 (0.40) HTR6HTR7HTR2AHTR2CMET
SCHEMBL4271798 0.86 HTR6 (0.50) HTR6HTR7HTR2AHTR2CMET
SCHEMBL4275875 0.84 MET (0.51) HTR6METSLC40A1MAPTNFE2L2
SCHEMBL3322506 0.83 TSHR (0.46) HTR6MAPTHSD11B1
SCHEMBL4280623 0.80 MET (0.48) HTR6HTR7HTR2AHTR2CMET
SCHEMBL4277387 0.80 MET (0.46) HTR6HTR7HTR2AHTR2CMET
SCHEMBL4277397 0.79 PKM (0.38) HTR6HTR7HTR2AHTR2CMAPT
SCHEMBL4272323 0.78 HTR6 (0.45) HTR6HTR7HTR2AHTR2CTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7608717-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-10-27 US claimed
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2008-03-20 US claimed
US-7291736-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-11-06 US claimed
EP-1648891-A1 SULFONYLDIHYDROIMID- AZOPYRIDINONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2006-04-26 EP claimed
WO-2005010003-A1 SULFONYLDIHYDROIMID- AZOPYRIDINONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-02-03 WO claimed
US-20050020596-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US claimed
US-7608717-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-10-27 US disclosed
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2008-03-20 US disclosed
US-7291736-B2 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2007-11-06 US disclosed
US-20050020596-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070943-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2C HTR6 1/4885HTR7 13/4885HTR2A 6/4885
US-20050020596-A1 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2C HTR6 1/4885HTR7 13/4885HTR2A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.